WARRINGTON, Pa., Oct. 10, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that additional clinical data from its SELECT and STAR Phase 3 clinical trials of Surfaxin(r) (lucinactant), for the prevention of Respiratory Distress Syndrome (RDS) in premature infants, were presented at the European Academy of Paediatrics Congress (Europaediatrics) in Barcelona, Spain. These data demonstrate that Surfaxin-treated infants require significantly less re-intubation and experience improved key clinical outcomes compared to those treated with the animal derived surfactants, Survanta(r) and Curosurf(r), the current market-leading products in the United States and Europe, respectively.
